38
Participants
Start Date
May 28, 2016
Primary Completion Date
April 10, 2018
Study Completion Date
April 30, 2018
SAB-301
SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
Normal (9%) Saline
Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
National Institutes of Health Clinical Center, Bethesda
Collaborators (1)
Naval Medical Research Center
FED
SAb Biotherapeutics, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH